Trazodone News and Research

RSS

Hypnotic drug class may not have increased the risk of exacerbations and death among COPD patients

Chronic obstructive pulmonary disease patients newly prescribed non-benzodiazepine benzodiazepine receptor agonists (NBZRAs) such as zolpidem (Ambien, Intermezzo and other brands), a class of hypnotic drugs prescribed for insomnia, did not have an increased risk of exacerbations requiring hospitalizations or of death than those prescribed other types of hypnotics, according to research published at the ATS 2023 International Conference.

24 May 2023

Sleep medications increase the risk of dementia in whites, study shows

A new study shows that sleep medications increase the risk of dementia in whites. But the type and quantity of the medication may be factors in explaining the higher risk.

31 Jan 2023

Young people treated for sleep disorders with benzodiazepines may be at higher risk of overdose

Teens and young adults who are treated for sleep disorders with benzodiazepines such as Xanax – a medication commonly prescribed to treat anxiety and insomnia – may be at a higher risk of overdose, according to Rutgers researchers.

23 Nov 2022

Nearly 1% of all US adults prescribed opioids are also taking various other sedatives

As many as 2.6 million Americans—equivalent to 1 per cent of all US adults —prescribed opioids are also taking various other sedatives, including benzodiazepines plus another type of sedative drug, estimates research published online in the journal Regional Anesthesia & Pain Medicine.

23 Feb 2022

Taking "z-drugs" with opioids increases risk of death

A new study by Vanderbilt University Medical Center researchers of more the 400,000 Medicare patients taking medications for insomnia found that the risk of death is increased when either benzodiazepines or "z-drugs" are taken with opioids.

16 Jul 2021

Melatonin may increase survival chances among intubated COVID-19 patients

Researchers at Columbia University in New York have conducted a study showing that patients with coronavirus disease 2019 (COVID-19) who require intubation and mechanical ventilation due to respiratory distress may benefit from treatment with the hormone melatonin.

19 Oct 2020

Coping with adult nightmares

Bad dreams or nightmares affect not only children but adults, too. Haunting nightmares can affect a person’s sleep quality and duration, but is it possible to turn off a nightmare while it is happening?

17 Feb 2020

New approach to reduce toxic protein production in ALS

Patients with ALS frequently have a string of repeated DNA code in the cells of their brain, carrying hundreds to thousands of copies within the gene C9orf72.

22 Jan 2019

$Alternative drug linked with comparable risk of falls, major fractures as atypical antipsychotics in older dementia patients$

Alternative drug linked with comparable risk of falls, major fractures as atypical antipsychotics in older dementia patients

As physicians attempt to decrease antipsychotic use in seniors with dementia, they need to be aware that trazadone, frequently used as an alternative, is associated with a similar risk of falls and major fractures as atypical antipsychotics, according to new research in CMAJ.

26 Nov 2018

Medical cannabis provides relief across dozens of health symptoms, study shows

Utilizing new mobile application technology, researchers at The University of New Mexico found that medical cannabis provides immediate symptom relief across dozens of health symptoms with relatively minimal negative side effects.

11 Sep 2018

Older people treated with electroconvulsive therapy for depression may not get relief from insomnia

Older people receiving electroconvulsive therapy for their depression likely will need an additional treatment if insomnia is one of their symptoms, researchers report.

16 Aug 2017

Physician's choice of insomnia medication may be based on habit, new research shows

Clinical decision-making is a complex process, driven by multiple factors, including social and psychological dynamics, peer pressure and even exposure to drug advertising.

15 Feb 2017

S1 Biopharma supports FDA's approval of flibanserin for women living with HSDD

S1 Biopharma is a developer of first-in-class drugs for sexual dysfunction in both women and men. The company's lead compound, Lorexys, is currently in Phase IIb for the treatment of hypoactive sexual desire disorder (HSDD).

20 Aug 2015

Pediatric migraine drugs show limited or no efficacy

There is limited evidence supporting the efficacy of trazodone and topiramate in the prevention of pediatric episodic migraine headaches, show results from a meta-analysis.

30 Jan 2013

Janssen’s NUCYNTA ER tablets more effective in providing pain management in adults with DPN

Janssen Pharmaceuticals, Inc. today announced the results of an investigational Phase 3 study suggesting NUCYNTA ER (tapentadol) extended-release tablets were significantly more effective than placebo in providing pain management among adults with chronic moderate to severe, painful diabetic peripheral neuropathy.

18 May 2012

Physician Therapeutics publishes results from Sentra PM clinical trial

Physician Therapeutics, Inc., a division of Targeted Medical Pharma, Inc., a specialty pharmaceutical company that manufactures and distributes specialty pharmaceuticals to physicians, pharmacies and skilled nursing facilities, published results from a clinical trial of the proprietary medical food Sentra PM.

3 May 2012

SSRI use raises risk of fall among elderly with dementia: Study

A new study reveals that nursing home residents with dementia who use selective serotonin reuptake inhibitors (SSRIs) have an increased risk of having a fall that causes injury compared with those who do not use SSRIs. Additionally those using average doses have 3 times the risk compared with nonusers, the authors, led by Carolyn S. Sterke, from Erasmus University Medical Center, Rotterdam, the Netherlands, report. Authors write, “Even at low doses, SSRIs are associated with increased risk of an injurious fall in nursing home residents with dementia.”

22 Jan 2012

J&JPRD submits NUCYNTA ER sNDA to FDA for DPN associated neuropathic pain

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. announced today that it has submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for NUCYNTA ER (tapentadol) extended-release tablets, an oral analgesic, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults.

31 Oct 2011

New generation antidepressants may increase risk of adverse outcomes in elderly

Older people taking new generation antidepressants are at more risk of dying or suffering from a range of serious health conditions including stroke, falls, fractures and epilepsy, a study involving researchers at The University of Nottingham has found.

3 Aug 2011

Labopharm, Angelini enter into agreement to reorganize partnership

Labopharm Inc. and Gruppo Angelini, its partner in the joint venture established by the two companies to commercialize OLEPTRO in the U.S., today announced that they have entered into an agreement to restructure their partnership.

30 Jul 2011